California Spectrum 1 profiles Steven Rosen, an oncologist-poet

How City of Hope is turning microbiome science into better cancer care

For years, clues pointed to the gut microbiome as a key factor in cancer treatment outcomes. Recent advances in gene sequencing are now clarifying its influence on how patients respond to therapy.

May 15, 2026

Vol.52 No.19

By Marcel van den Brink and Robert Jenq

In Brief

City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers

Quest Diagnostics, a provider of diagnostic information services, announced that City of Hope is implementing Haystack MRD, a circulating-tumor DNA minimal residual disease test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast, colorectal, ovarian, and prostate cancer.

April 24, 2026

Vol.52 No.16

Sponsored

Bridging communication and genomics: A path toward equitable cancer care

The era of genomic oncology is defined by complexity. Over the last decades, we have moved from single-gene tests to multi-gene panels and, eventually, will be routinely using whole-exome/whole-genome and transcriptome sequencing in clinical care.

Early-onset colorectal cancer demands a new research playbook

Colorectal cancer is no longer a disease confined to older adults.

California Institute of Regenerative Medicine and Cancer Research: A promise broken?

Approximately 21 years ago, I had the privilege of working and helping to pass Proposition 71, which authorized $3 billion dollars in state bonds to fund stem cell research in California.

February 20, 2026

Vol.52 No.07

By Stephen J. Forman